Detalhe da pesquisa
1.
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
N Engl J Med
; 387(4): 310-320, 2022 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35830649
2.
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Br J Haematol
; 194(1): 120-131, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34036560
3.
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Blood
; 134(2): 123-133, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30862646
4.
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Future Oncol
; 17(34): 4797-4812, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521277
5.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Lancet
; 394(10214): 2096-2107, 2019 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31735560
6.
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Blood
; 129(25): 3294-3303, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28483761
7.
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
Br J Cancer
; 119(12): 1471-1476, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425349
8.
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
Future Oncol
; 14(11): 1035-1047, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29268619
9.
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Haematologica
; 107(3): 774-775, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35229573
10.
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Haematologica
; 106(4): 1182-1187, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32586908
11.
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Breast Cancer Res Treat
; 154(2): 287-97, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26497877
12.
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 149(1): 151-61, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25537644
13.
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Gynecol Oncol
; 136(2): 246-53, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25528496
14.
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
Clin Lymphoma Myeloma Leuk
; 22(8): e751-e761, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641409
15.
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Leukemia
; 35(12): 3526-3533, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34050260
16.
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Leuk Res
; 104: 106576, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33839618
17.
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Leukemia
; 35(2): 562-572, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32444867
18.
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
Oncologist
; 15(8): 799-809, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20671105
19.
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
CPT Pharmacometrics Syst Pharmacol
; 9(11): 649-658, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33021075
20.
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Cells
; 8(12)2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31779273